

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO PLACING OF NEW SHARES UNDER GENERAL MANDATE

Placing Agent

華通證券國際

— Waton Securities International Limited —

Waton Securities International Limited

Reference is made to the announcement of the Company dated 28 March 2024 in relation to the Placing (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this supplemental announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, the gross proceeds and the Net Proceeds (after deducting the placing fee and other related expenses incurred in the Placing) from the Placing are expected to be HK\$39.0 million and approximately HK\$37.7 million, respectively.

The Company would like to supplement further information in relation to the use of the Net Proceeds that (i) approximately 26.5% of the Net Proceeds (representing approximately HK\$10 million) will be used for opening up clinics in China for expansion of the clinic network; (ii) approximately 63.5% of the Net Proceeds (representing approximately HK\$23.9 million) will be used for repayment of outstanding loans which will become due; and (iii) approximately remaining 10% of the Net Proceeds (representing approximately HK\$3.8 million) will be used as general working capital of the Group.

Save as the supplemental information as disclosed above, all other information contained in the Announcement remains unchanged.

Shareholders and potential investors should note that the Placing is subject to the fulfilment of the condition under the Placing Agreement as set out in the section headed “Condition of the Placing” in the Announcement and the Placing Agreement may be terminated by the Placing Agent at any time up to 8:00 a.m. on the date of Completion. As the Placing may or may not proceed to Completion, Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman and Executive Director

Hong Kong, 5 April 2024

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham and Ms. Man Yee Wai, Viola; the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.